ReviewFrontiers in immunology2026
Unlocking the therapeutic potential of traditional Chinese medicine in Crohn's disease: from multi-target mechanisms to clinical promise.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Crohn's disease (CD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract with an unclear etiology. Current Western therapies, including 5-aminosalicylates, corticosteroids, biologics, and immunomodulators, often fail to maintain sustained remission and are associated with significant adverse effects and high recurrence rates following drug withdrawal. Traditional Chinese medicine (TCM) has shown potential in alleviating CD symptoms through multi-target and multi-pathway mechanisms. Thus, this review aims to systematically summarize recent advances in understanding the mechanisms by which TCM intervenes in CD, focusing mainly on: regulating immune balance (including modulation of Th1/Th2, Th17/Treg, and M1/M2 macrophage polarization), attenuating inflammatory cascades (via NF-κB, MAPK, PI3K/AKT, and JAK/STAT pathways), reducing oxidative stress, regulating programmed cell death in intestinal epithelial cells (including apoptosis, pyroptosis, ferroptosis, and autophagic cell death), enhancing intestinal mucosal barrier integrity, and promoting restoration of intestinal microbial homeostasis. Furthermore, TCM combined with Western therapies may exert synergistic effects to improve clinical efficacy and reduce relapse risk. Future research could further integrate network pharmacology and multi-omics technologies to elucidate the molecular mechanisms of TCM more deeply, advancing precision therapeutics for CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.